Organon & Co. (NYSE:OGN) Shares Sold by Keeley Teton Advisors LLC

Keeley Teton Advisors LLC reduced its stake in Organon & Co. (NYSE:OGN) by 14.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 47,323 shares of the company’s stock after selling 7,778 shares during the period. Keeley Teton Advisors LLC’s holdings in Organon & Co. were worth $706,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in OGN. Wellington Management Group LLP purchased a new stake in Organon & Co. in the third quarter valued at $437,000. Barclays PLC lifted its holdings in shares of Organon & Co. by 238.0% in the 3rd quarter. Barclays PLC now owns 119,483 shares of the company’s stock valued at $2,285,000 after purchasing an additional 84,136 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Organon & Co. by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 4,248,108 shares of the company’s stock valued at $81,288,000 after purchasing an additional 82,220 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in Organon & Co. during the 3rd quarter worth approximately $185,000. Finally, Optimist Retirement Group LLC acquired a new position in Organon & Co. during the third quarter worth approximately $1,974,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Stock Down 2.0 %

Shares of NYSE:OGN opened at $10.83 on Thursday. Organon & Co. has a fifty-two week low of $10.75 and a fifty-two week high of $23.10. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The firm’s 50-day simple moving average is $14.40 and its 200-day simple moving average is $15.52. The company has a market cap of $2.79 billion, a price-to-earnings ratio of 3.25, a PEG ratio of 0.90 and a beta of 0.73.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). The business had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. As a group, equities research analysts predict that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were given a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 10.34%. The ex-dividend date of this dividend was Monday, February 24th. Organon & Co.’s payout ratio is 33.63%.

Wall Street Analysts Forecast Growth

OGN has been the subject of several research analyst reports. Morgan Stanley decreased their price objective on Organon & Co. from $16.00 to $15.00 and set an “equal weight” rating for the company in a report on Wednesday, April 9th. Barclays lowered their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Finally, TD Cowen raised shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $20.60.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.